Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association

Saved in:

Bibliographic Details
Main Authors:	Alexander D. Woods, MD, Katelyn Kim, MD, Anna Axelson, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	JAAD Case Reports
Subjects:	CTLA-4 inhibitors cutaneous immune-related adverse events hidradenitis suppurativa immune checkpoint inhibitors PD-1 inhibitors
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512624004934
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
by: Travis C. Frantz, MD, et al.
Published: (2025-03-01)

Hidradenitis Suppurativa-Like Tuberculosis: A Warning for Dermatologists
by: Jose Paulo Ribeiro Junior, et al.
Published: (2025-01-01)

Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association
by: Martora F, et al.
Published: (2025-01-01)

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa
by: Zahidul Islam, BA, et al.
Published: (2025-02-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Acquired Lymphangioma Circumscriptum of Vulva in a Patient With Hidradenitis Suppurativa: A Rare Case at a Rare Site
by: Ranju Pokharel, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Immediate versus Delayed Wound Closure in Hidradenitis Suppurativa Surgery: A Comparative Outcomes Study
by: Ehud Fliss, et al.

Hidradenitis Suppurativa Prevalence by Age and Race in the United States
by: Kritin K. Verma, et al.
Published: (2024-12-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Oral manifestation associated with avelumab
by: Kevin Chung, et al.
Published: (2024-03-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Demographic features, clinical characteristics, and comorbid relation in hidradenitis suppurativa: a population-based study
by: Gökhan Kaya, et al.
Published: (2025-01-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Unusual gingival presentation following treatment with pembrolizumab
by: Annu Singh, et al.
Published: (2024-03-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Clinical Epidemiology and Phenotypic Characteristics of Hidradenitis Suppurativa Disease in the Central Region of Saudi Arabia: Findings from a Cross-Sectional
by: Alotaibi H, et al.
Published: (2025-01-01)

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
by: Gloria Juan-Carpena, et al.
Published: (2025-01-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report
by: Tomoyuki Otsuka, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma
by: Daniel S. Alicea, MS, et al.
Published: (2025-03-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial
by: Verena Theiler-Schwetz, et al.
Published: (2025-12-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01)

Multifocal disseminated necrotizing leukoencephalopathy as severe central nervous system toxicity from nivolumab therapy for Hodgkin lymphoma: a case report
by: Hussein Algahtani, et al.
Published: (2025-01-01)